The India Minimal Residual Disease Market was valued at $22.1 Million in 2024 and projected to reach to $41.7 Million by 2029, representing a compound annual growth rate of 13.5%. India's Minimal Residual Disease market is poised for sustained growth driven by increasing cancer prevalence, healthcare infrastructure development, and rising awareness among oncologists and hematologists.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
India's MRD market is valued at $22.1 million in 2024 and is projected to reach $41.7 million by 2029, representing an impressive 13.5% CAGR, outpacing the global growth rate of 12.2%.
Increasing incidence of blood cancers and leukemias in India is driving demand for advanced MRD diagnostic solutions to improve patient outcomes and enable early intervention strategies.
Indian healthcare facilities are progressively integrating MRD testing into clinical protocols, supported by government initiatives and private sector investments in diagnostic capabilities.
Growing adoption of flow cytometry, PCR-based testing, and next-generation sequencing technologies in Indian diagnostic centers is expanding MRD testing accessibility across tier-1 and tier-2 cities.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | MULTIPLE MYELOMA (Application) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 12.2% from 2024 to 2029 |
| Largest Segment | ASSAY KITS & REAGENTS (Product) |
| Market Size Base Year (Billions) | ~USD 1.43 (2024) |
| Revenue Forecast (Billions) | ~USD 2.55 (2029) |
| Segments Covered | Product, Technology, Application, Type, End User |
5 segment dimensions are covered across the global market.
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 3.8 | 4.3 | 5 | 5.6 | 6.4 | 7.3 | 8.2 | 9.3 | 13.2 |
| DIAGNOSTIC LABORATORIES | 8 | 9.2 | 10.7 | 12.4 | 14.3 | 16.4 | 18.8 | 21.6 | 15.1 |
| HOSPITALS & SPECIALTY CLINICS | 11.6 | 13.4 | 15.1 | 17.3 | 19.6 | 22.2 | 25.2 | 28.2 | 13.3 |
| OTHER END USERS | 2 | 2.3 | 2.7 | 3.1 | 3.5 | 4 | 4.5 | 5.1 | 13.6 |
| TOTAL | 25.4 | 29.2 | 33.5 | 38.4 | 43.8 | 49.9 | 56.7 | 64.2 | 13.9 |
India's Minimal Residual Disease market was valued at $22.1 million in 2024 and is expected to reach $41.7 million by 2029.
India's MRD market is projected to grow at a compound annual growth rate (CAGR) of 13.5% from 2024 to 2029.
India's 13.5% CAGR exceeds the global 12.2% rate due to rising cancer prevalence, increasing adoption of precision diagnostics, expanding healthcare infrastructure, and government support for advanced oncology testing.
Key drivers include growing hematologic malignancy prevalence, increased awareness among oncologists, improved access to molecular diagnostics, rising healthcare expenditure, and government initiatives supporting cancer care infrastructure.
By 2029, India is expected to consolidate its position as a leading MRD market in Asia Pacific, with widespread adoption across metropolitan and tier-2 cities, supported by continued infrastructure investments and healthcare spending growth.
This study involved four major activities in estimating the current size of the minimal residual disease testing market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2022/2023, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
To know about the assumptions considered for the study, download the pdf brochure
| COMPANY NAME | DESIGNATION |
|---|---|
| Roche Ltd. | General Manager |
| Gaurdant | Area Sales Manager |
Both top-down and bottom-up approaches were used to estimate and validate the minimal residual disease testing market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
The research methodology used to estimate the market size includes the following:

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Minimal Residual Disease (MRD) refers to the small number of cancer cells left in a body after cancer treatment. MRD tests are performed to diagnose and monitor patients with various hematology cancers, such as leukemia, lymphoma, and myeloma. An MRD test looks for cancer cells not killed by chemotherapy or other cancer treatments. Moreover, these tests also play a crucial role in clinical trials of hemato-oncology therapeutics.
Full forecast, segment splits, and company analysis for all Minimal Residual Disease Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report